1050 Ivosidenib is being tested in trials for combination therapies with other cancer drugs, including a phase III trial with azacitidine (NCT 03173248), a phase I trial with cytarabine and fludarabine (NCT 04250051), and a phase I/II trial with venetoclax (NCT 03471260)
Mar 2017;156(3):543-548
There are no known serious adverse effects at physiologically relevant doses
Typical progression: Week 12 Improved energy levels Week 34 Better endurance Week 6+ Gradual fat loss Studies indicate modest fat loss (~1 kg over time) when combined with exercise
Another phase III, randomized, open-label, non-inferiority, head-to-head trial, AWARD-6, evaluated dulaglutide (1.5 mg) versus liraglutide (1.8 mg) in patients with T2DM
Phenoxyethanol, a synthetic compound commonly used as a preservative in personal care products, helps to maintain their stability and shelf life